Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.37 |
| ▸ | KMO | O15229 | 3/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13641471 | 0.84 | HTR2A (0.43) | PKMSLC9A1KMOGRM2HTR2A | |
| SCHEMBL1980738 | 0.79 | TNF (0.43) | KMO | |
| SCHEMBL12600918 | 0.78 | KMO (0.32) | KMO | |
| SCHEMBL8804551 | 0.78 | PKM (0.36) | PKMSLC9A1KMOGRM2 | |
| SCHEMBL21780866 | 0.78 | KMO (0.46) | PKMSLC9A1KMOHCAR3TLR8 | |
| SCHEMBL1542251 | 0.77 | NOTUM (0.36) | — | |
| SCHEMBL15687678 | 0.76 | HTR2A (0.47) | KMOGRM2HTR2AHTR2CHTR2B | |
| SCHEMBL13641438 | 0.75 | HTR2A (0.34) | PKMKMOALDH1A1TDP1LMNA | |
| SCHEMBL2945239 | 0.73 | PKM (0.41) | PKMSLC9A1GRM2 | |
| SCHEMBL16418009 | 0.72 | BRD4 (0.45) | PKMKMOALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283297-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO WELLCOME HOUSE (GB) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283297-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR2 | PKM 2024/4885SLC9A1 2502/4885KMO 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.